Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8Genitourinary 4Gynecologic 2Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Leukemia, Hairy Cell 1

Interventions

venetoclax 152Cytarabine 114Cyclophosphamide 110Specimen Handling 101Azacitidine 99fludarabine 89Biopsy 76Rituximab 48Methotrexate 45Daunorubicin 44fludarabine phosphate 42Vincristine 38Dexamethasone 37Magnetic Resonance Spectroscopy 36Injections 34Decitabine 34blinatumomab 31Granulocyte Colony-Stimulating Factor 30Mycophenolic Acid 29Whole-Body Irradiation 28Prednisone 28Idarubicin 28ibrutinib 27Tacrolimus 27Etoposide 27Doxorubicin 27Busulfan 27Melphalan 24acalabrutinib 23Mercaptopurine 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Energy Shock Waves × Other hematologic neoplasm × 90 days × Clear all
NCT01841723 2026-05-13

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
44 enrolled
Other hematologic neoplasm

Leukemia, Hairy Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡